MIKOBAKTERIOZE ‒ NEKAD I SAD
Sažetak
Netuberkulozne mikobakterije (NTM) su ubikvitarne i nalaze se svuda u okolini. Ljudi su svakodnevno izloženi kontaktu sa ovim mikroorganizmima. Dok broj slučajeva obolelih od tuberkuloze (TB) u celom svetu opada, učestalost infekcija izazvanih NTM je u porastu. NTM mogu uzrokovati kako asimptomatsku infekciju, tako i simptomatsku bolest kod ljudi. Najčešće su plućne infekcije različitog stepena težine. Tačna dijagnoza veoma je važna, između ostalog i zbog toga što lekovi koji se koriste u lečenju ove bolesti mogu imati značajne sporedne efekte. Terapija mikobakterioza, uopšteno, nije direktno analogna terapiji tuberku-loze. Empirijska terapija se ne preporučuje. In vitro osetljivost mnogih NTM nije u korelaciji sa kliničkim odgovorom na antimikobakterijske lekove.
Reference
Adjemian J, Daniel-Wayman S, Ricotta E, Prevots DR. Epidemiology of Nontuberculous Mycobacteriosis. Semin Respir Crit Care Med. 2018;39(3):325-35. [CrossRef] [PubMed]
Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiares. Am J Respir Crit Care Med. 2012;185(8):881-6. [CrossRef] [PubMed]
Andréjak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontruberculous pul-monary mycobacteriosis in Denmark: incidence and prognostic factors. Am J respire Crit Care Med. 2010; 18(1):514-21. [CrossRef] [PubMed]
Ceron J, Pastor A, Sole A, Jorda C, Escriva J, Padilla J. Lung transplatation: Mycobacterium abscessus as a cause of graft dysfunction. Breath. 2007;3(3):291-5. [CrossRef]
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):1-36. [CrossRef] [PubMed]
Đurić O, Škodrić V, Vučinić V, Savić B. Oboljenja uzrokovana oportunističkim mikobakterijama-miko-bakterioze. Tuberkuloza. Savremena administracija. Beograd. 1996;366-406.
Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung decline in cystic fibrosis. J Cyst Fibros. 2010; 9(2):117-23. [CrossRef] [PubMed]
Global Tuberculosis Report. WHO. 2019.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. American Thoracic Society Document. An Official ATS/IDSA Statment, Diagnosis, Treatment, and Prevention of Nontuberculous Disea-ses. Am J Respir Crit Car Med. 2007;175(4):367-416. [CrossRef] [PubMed]
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. BTS Guidlines for the mena-gement of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(2):1-64. [CrossRef] [PubMed]
Hoefsloot W, van Ingen J, Magis-Escurra C, Reijers MH, van Soolingen D, Dekhuijzen RP, et al. Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations. J Infect. 2013;66:542-5. [CrossRef] [PubMed]
Honda JR, Knight V, Chan ED. Pathogenesis and risk factors for nontuberkulous mycobacterial lung disease. Clin Chest Med. 2015;36(1):1-11. [CrossRef] [PubMed]
http://www.bacterio.net/ mycobacterium.html
Jankovic M, Sabol I, Zmak L, Jankovic VK, Jakopovic M, Obrovac M, et al. Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. Int J Tuberc Lung Dis. 2016;20(7):934-40. [CrossRef] [PubMed]
Joint Tuberculosis Committee BTS. Menagment of opportunist mycobacterial infections: Joint Tubercu-losis Committee guidlines 1999. Thorax. 2000;55: 210-8. [CrossRef] [PubMed]
Katalinić –Janković V., Popović GS, Obrovac M, Cvetnić Ž, Alfirević T. Infekcije izazvane netuberku-loznim mikobakterijama. Lječnički vjesnik. 2007; 129(5):146-51. [PubMed]
Kim SY, Han SA, Kim DH, Koh WJ. Nontuberculous mycobacterial lung disease: ecology, microbiology, pathogenesis, and antibiotic resistance mechanisms. Precision and Future Medicine. 2017;1(3):99-114. [CrossRef]
Lin C, Russell C, Soll B, Chow D, Bamrah S, Brostrom R, et al. Increasing Prevalence of Nontuberculous Mycobacteria in Respiratory Specimens from US-Affiliated Pacific Island Juridictions. Center for Disease Control and Prevention, EID journal. 2018;24(3): 485-91. [CrossRef] [PubMed]
McGrath EE, McCabe J, Anderson PB. Guidelines on the diagnosis and treatment of pulmonary non-tuber-culous mycobacteria infection. Int J of Clin Pract. 2008;62(12):1947-55. [CrossRef] [PubMed]
Park SC, Kang MJ, Han CH, Lee SM, Kim CJ, Lee JM, et al. Prevalence, incidence, and mortality of non-tuberculous mycobacterial infection in Korea: a nationwide population-based study. BMC Pulm Med. 2019;19(1):140. [CrossRef] [PubMed]
Prevots DR, Marras KT. Epidemiology of Human Pulmonary Infection with NonTuberculous Mycobac-teria: A Review. Clin Chest Med. 2015;36(1):13-34. [CrossRef] [PubMed]
Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacte-ria: a review. Clin Chest Med. 2015;36(1):13-34. [CrossRef] [PubMed]
Procop GW, Church DL, Hall GS, Janda WM, Koneman EW, Schreckenberger PC, et al. Konemans Color Atlas and Textbook of Diagnostic Microbiology 7th edition. Chapter XIX. Philadelphia: Wolters Kluwer Health. 2017;1219-68.
Rivero-Lezcano OM, González-Cortés C, Mirsaeidi M. The unexplained increase of nontuberculous myco-bacteriosis. Int J Mycobacteriol. 2019;8:1-6. [CrossRef] [PubMed]
Sekulić S. Mikobakterioze. Plućne bolesti. Elit-Medica. Beograd. 2000;425-7.
The Research Committee of the British Thoracic Society. Pulmonary disease coused by M. malmoense in HIV negative patients: 5-yr follow-up of patients reciving standardied treatment. Eur Respir J. 2003;21 (3):478-82. [PubMed]
van Ingen J, Bendien SA, de Lange WC, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64(6):502-6. [CrossRef] [PubMed]
Van Ingen J, Turenne CY, Tortoli E, Wallace RJ Jr, Brown-Elliott BA. A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. Int J Syst Evol Microbiol. 2018;68(11): 3666-77. [CrossRef] [PubMed]
Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999.-2014. ATS journal. 2016;13(11):1951-5. [CrossRef] [PubMed]
Wallace RJ Jr, Cook JL, Glassroth J, Griffith DE, Olivier KN, Gordin F. An Official ATS/IDSA statement: diag-nosis and treatment of disease coused by non-tuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:1-25. [CrossRef]
Wang BY, Amolat MJ, Woo P, Brandwein-Gensler M. Atypical mycobacteriosis of the larynx: an unusual clinical presentation secondary to steroids inhalation. 2008;12(6):426-9. [CrossRef] [PubMed]
Wilson ML. Reducing the Global Burden of Myco-bacterial Infections One More Piece of the Puzzle. Am J Clin Pathol. 2008;130:849-52. [CrossRef] [PubMed]